Clinical trials: Chemoradiotherapy
Rectal Cancer
A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Neoadjuvant chemoradiotherapy (CRT) has been the standard therapy for local advanced rectal cancer. Pathological complete response (pCR) is an important prognostic factor for local control and survival.
- Trial name
- NCT01064999
- Testing
- Oxaliplatin, Capecitabine, Radiotherapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Fudan University
Rectal Cancer
Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers
Current therapy for early colorectal cancer is radical Total Mesorectal Excision (TME). Colorectal surgical resections are accompanied with high morbidity of up to 33% and 90 days mortality of up to 9% in the fragile elderly…
- Trial name
- TESAR (NCT02371304)
- Testing
- Adjuvant chemoradiotherapy, Additional TME surgery, capecitabine
- Where
- Netherlands
- Volunteers
- 302 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Cancer
Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer
Based on the neurophysiology, it is well known that sympathetic nerves control the ejaculatory function and bladder neck closure. In contrast, the parasympathetic nerves control penile erection and bladder wall contraction.
- Trial name
- NCT00154752
- Testing
- CCRT, Pelvic lymphadenoectomy.
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Nasopharyngeal Carcinoma
Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma
The primary objective of this study is to determine the tolerance and overall survival in patients with stage Ⅲ NPC treated with neoadjuvant chemotherapy and concurrent chemoradiation.
- Trial name
- NCT00816855
- Testing
- docetaxel, cisplatin, fluorouracil
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
This is a single-arm, multi-center, open-label, phase II trial to examine the efficacy of pembrolizumab for prolonging the one-year disease free survival in nasopharyngeal carcinoma patients with solely detectable EBV DNA after…
- Trial name
- NCT03544099
- Testing
- Pembrolizumab
- Where
- 8 sites in Taiwan
- Volunteers
- 2 people
- Sponsor
- National Health Research Institutes, Taiwan
Nasopharyngeal Carcinoma
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
By this clinical trial, the investigators are trying to give an answer to such a question. Whether NPC patients staged N2-3M0 need adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation?
- Trial name
- NCT01694576
- Testing
- Adjuvant chemotherapy with paclitaxel and nedaplatin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Cancer
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01074021
- Testing
- Nimotuzumab
- Where
- 24 sites in China
- Volunteers
- 480 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
This is a randomized, prospective, multicenter study.
- Conditions
- Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy, Chemoradiotherapy
- Trial name
- NCT02399306
- Testing
- Enteral nutrition, radiotherapy
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Rectal Cancer
KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer
This phase II clinical trial is evaluating whether adding KRC-01 injections to standard chemoradiotherapy may improve treatment outcomes in patients with locally advanced rectal cancer without metastases.
- Trial name
- K-BOOST (NCT07622017)
- Testing
- KRC-01 (KORTUC), Radiotherapy, Capecitabine
- Where
- 2 sites in France
- Volunteers
- 24 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Head and Neck Cancer
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01142414
- Testing
- panitumumab, cisplatin, fluorouracil
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Esophageal Squamous Cell Carcinoma
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
This is a multicenter, open-label, randomized, controlled clinical study to compare the efficacy and safety of cardonilizumab combined with neoadjuvant chemotherapy and surgery versus neoadjuvant chemoradiotherapy and surgery in…
- Trial name
- NCT07699185
- Testing
- Cardonilizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Tongji Hospital
Locally Advanced Rectal Cancer
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
The study evaluates the addition of Amifostine to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer.
- Trial name
- NCT03702985
- Testing
- Radiation, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Cancer of Esophagus
Surgery As Needed for Oesophageal Cancer - 2
A prospective cohort study on active surveillance after neoadjuvant chemoradiation for oesophageal cancer: SANO-2 study.
- Trial name
- SANO-2 (NCT04886635)
- Testing
- Active surveillance
- Where
- Netherlands
- Volunteers
- 360 people
- Sponsor
- Bas P. L. Wijnhoven
Locally Advanced Rectal Cancer (LARC)
A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer
This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II clinical trial to determine the efficacy and clinical complete response rate in patients with rectal cancer and tumor preoperative evaluation…
- Trial name
- NCT04009876
- Testing
- nal-IRI, Surgical resection, Watch-and-wait
- Where
- 4 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de investigación HM
Extensive-stage Small-cell Lung Cancer
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
Open-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy of immunotherapy with durvalumab concomitant with radiochemotherapy, followed by durvalumab maintenance therapy in combination with…
- Trial name
- NCT06223711
- Testing
- Thoracic Radiochemotherapy, durvalumab, Stereotactic radiotherapy of further tumor locations
- Where
- 5 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Universität des Saarlandes
Rectal Cancer Patients
Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
This study is a prospective, single-arm, phase II superiority trial to determine whether a selective organ-preserving strategy based on immediate intra-operative frozen-section results can achieve favorable 2-year local control…
- Trial name
- NCT07337811
- Testing
- Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
Lymph Node Metastasis, Neurovascular Invasion
Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）
The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can…
- Conditions
- Lymph Node Metastasis, Neurovascular Invasion, Pathology Showed R1 Resection
- Trial name
- AICRC (NCT06997913)
- Testing
- Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk resectable Extrahepatic Cholangiocarcinoma（AICRC）
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hengchao Yu
Esophageal Cancer, Immunotherapy
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for…
- Conditions
- Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
- Trial name
- NCT06421376
- Testing
- Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Adenocarcinoma
Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma
1. Target population: patients with resectable locally advanced proximal (including gastroesophageal junction, fundus and upper body) stomach adenocarcinoma (cT3-4aN+M0). 2.
- Trial name
- Neo-PLANET (NCT03631615)
- Testing
- Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-small Cell Lung Cancer
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
This study aims to evaluate the 1-year progression free survival (PFS) rate of tislelizumab combined with sitravatinib as assessed by investigators per RECIST 1.1.
- Trial name
- NCT05176925
- Testing
- Tislelizumab, Sitravatinib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.